Esperion Therapeutics Inc. (ESPR)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Esperion Therapeutics Inc. chart...

About the Company

esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.

CEO

Timothy Mayleben

Exchange

NASDAQ

Website

http://www.esperion.com/

$49M

Total Revenue

160

Employees

$242M

Market Capitalization

-0.94

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ESPR News

Q4 2023 Esperion Therapeutics Inc Earnings Call

20d ago, source: Yahoo Finance

Alexis Callahan; IR; Esperion Therapeutics, Inc. Sheldon Koenig; President & CEO; Esperion Therapeutics, Inc. Ben Halladay; CFO; Esperion Therapeutics, Inc. Eric ...

Esperion Therapeutics Stock (NASDAQ:ESPR), Quotes and News Summary

18d ago, source: Benzinga.com

Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 ...

Esperion Therapeutics Inc ESPR

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript

20d ago, source: Yahoo Finance

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript February 27, 2024 Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.5, expectations were $-0.53.

Esperion Therapeutics Inc 0ET

27d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript

20d ago, source: Insider Monkey

Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.5, expectations were $-0.53. Esperion Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at ...

Esperion Therapeutics Inc (ESPR)

20d ago, source: Investing

Esperion Therapeutics (NASDAQ:ESPR) has announced a robust performance for the fourth quarter and the full year, marked by a significant 72% increase in total revenue ...

Esperion Therapeutics, Inc. (ESPR) Q4 2023 Earnings Call Transcript

20d ago, source: Seeking Alpha

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Esperion’s Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...